'Death-rattle' (i.e 'terminal lung secretions') in adult patients dying from end-stage malignancy
Conditions
Interventions
Trade Name: TRANSIDERM NITRO 10
Product Name: TRANS-DERMAL NITRATE 10
Product Code: n/a
Pharmaceutical Form: Transdermal patch
INN or Proposed INN: n/a
CAS Number: n/a
Current Sponsor code: MJ/LPGB/12
Sponsors
St Raphael's Hospice, Surrey
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with advanced malignancy who enter the 'terminal phase' i.e (eligible for 'Integrated care pathway' for the dying) 2.Patients over 18 years of age Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: 1.Patients with Primary Brain Tumour 2.Patients with Cerebral Metastases 3.Patients with 'Motor Neurone Disease' 4.Patients with 'end-stage cardiac failure'
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Secondary Objective: 1.Reduce the perception of the severity of 'death-rattle' by the patient's 'loved ones', thereby postively impact on bereavement 2.Reduce staff's perception of the severity of 'lung secretions', thereby minimise staff' distress 3.Reduce the requirement for frequent extra doses of the standard anti-secretory agent use or the need for increase of the 24 hour dose of same, thereby minimising dry mouth, 'thirst element' for the unconscious, dying patient 4.Reduce the requirement for the use of parenteral (i.e s/c,i/m or i/v) Furosemide;Primary end point(s): 1. Maximum noise level ( in dB ) of the 'death-rattle' at mid-day (tested using CASTLE GA 208 sound level meter)-average of 3 readings- 2. Relative's perception of the severity of ''death-rattle''--as mild; moderate; or severe 3. Clinical staff's perception of the severity of ''lung secretions''--as mild; moderate or severe;Main Objective: Evaluate the efficacy of 'TRANS-DERMAL NITRATE' in reducing the severity of 'death-rattle' ( i.e 'terminal lung secretions') in adult patients dying from end-stage malignancy | — |
Countries
United Kingdom
Outcome results
None listed